March 10, 2008 – KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced the initiation of a Phase 1/2 clinical study of KB002, the company’s anti-GM-CSF monoclonal antibody, as a potential treatment for persistent asthma. The blinded, placebo-controlled study, which is being conducted at over five sites in Australia, will enroll up to 24 patients who will receive either KB002 or placebo. Endpoints for the study will include safety, measurements of Forced Expiratory Volume (FEV1 – a measurement of expiratory air flow), and inflammatory markers... KaloBios' Press Release -
Mar 11, 2008
KaloBios, Phase 1/2 Trial of KB002 Engineered Monoclonal Antibody in Persistent Asthma
March 10, 2008 – KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced the initiation of a Phase 1/2 clinical study of KB002, the company’s anti-GM-CSF monoclonal antibody, as a potential treatment for persistent asthma. The blinded, placebo-controlled study, which is being conducted at over five sites in Australia, will enroll up to 24 patients who will receive either KB002 or placebo. Endpoints for the study will include safety, measurements of Forced Expiratory Volume (FEV1 – a measurement of expiratory air flow), and inflammatory markers... KaloBios' Press Release -
